Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide with R-DHAP for Relapsed/Refractory Aggressive B-cell NHL
NCT02983097Phase 2Terminated
- Sponsor
- GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie
- Start
- Nov 2010
- Primary completion
- Jan 2014
- Countries
- 1
01
Overview
A Phase 2 trial of lenalidomide in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), Burkitt lymphoma (BL), marginal zone lymphoma (MZL), sponsored by GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie. Started Nov 2010; status: terminated.
02
Drugs
lenalidomide
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)mantle cell lymphoma (MCL)Burkitt lymphoma (BL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT02983097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02983097.